PennyMac Financial Services, Inc. Announces Date for Release of First Quarter 2026 Results

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- PennyMac Financial Services, Inc. (NYSE: PFSI) will announce results for the quarter ended March 31, 2026, in a news release to be issued after the market close on Tuesday, May 5, 2026. Management will also host a conference call and live audio webcast at 5:00 p.m. Eastern Time to review the results.

The release, webcast, and accompanying materials will be available online at pfsi.pennymac.com. A replay of the webcast will be available shortly after its conclusion.

Individuals who are unable to access the website but would like to receive a copy of the materials should contact our Investor Relations department at 818.264.4907.

About PennyMac Financial Services, Inc.

PennyMac Financial Services, Inc. is a specialty financial services firm focused on the production and servicing of U.S. mortgage loans and the management of investments related to the U.S. mortgage market. Founded in 2008, the company is recognized as a leader in the U.S. residential mortgage industry and employs approximately 4,900 people across the country. In 2025, PFSI’s production of newly originated loans totaled $145 billion in unpaid principal balance, making it a top lender in the nation. As of December 31, 2025, PFSI serviced loans totaling $734 billion in unpaid principal balance, making it a top mortgage servicer in the nation. Additional information about PennyMac Financial Services, Inc. is available at pfsi.pennymac.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260420079818/en/

Media
Kristyn Clark
[email protected]
805.395.9943

Investors
Kevin Chamberlain
Isaac Garden
[email protected]
818.264.4907

Source: PennyMac Financial Services, Inc.

You May Also Be Interested In

• PENN Entertainment Celebrates the Official Opening of New Hotel at Hollywood Casino Columbus
• Invitation Homes Announces Cash Dividend
• Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million